UPC Roundup; Avanci EV Charger progress; Fed. Cir. AstraZeneca ruling; GaN patent wars

1) Premium: UPC Roundup (1 week): CoA clarifies PI costs; evidence production curtailed; PMAC moves on FRAND guidelines; and more

This is a summary of developments in and around the UPC in the calendar week of July 5, 2026.

2) Premium: Federal Circuit upholds decision to throw out $107.5M patent infringement verdict against AstraZeneca

The precedential decision, confirming the invalidation of two of Pfizer subsidiary Wyeth’s cancer drug-related patents, held that the plaintiff not only failed to rebut evidence on certain issues, but its own experts agreed against it.

3) Premium: Gallium nitride patent suit docket stacks up in the U.S.

Semiconductor tech maker Wolfspeed has filed a gallium nitride-related patent complaint against rival Navitas Semiconductor over the alleged infringement of five of its patents.

4) Free: Lenovo and China Telecom join Avanci EV Charger program as licensors; Japanese licensee signs up

It’s a continuation of a theme for the pool operator, which has seen a boom in the number of Asian companies joining its programs in recent months.